United States-based Xeris Pharmaceuticals has started dosing patients in a phase two trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type one diabetes who experience episodes of exercise-induced hypoglycaemia, it was reported on Friday.

This Phase two study will assess Xeris' ready-to-use glucagon as a pre-treatment to prevent exercise-induced hypoglycaemia in 48 patients with Type one diabetes who receive daily insulin treatment through a subcutaneous infusion pump. In the two-period cross-over comparison study, patients will receive ready-to-use glucagon or placebo at least 45 minutes before moderate or high intensity aerobic exercise in a clinical research centre. Additional data will then be collected through a parallel comparison in an outpatient setting with a similar regimen involving at least 30 minutes of aerobic exercise performed by subjects 3-5 times per week for 12 weeks.

Xeris Pharmaceuticals expects top-line results from the study in the second half of 2019.